Leidos Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Leidos Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $17.17B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $16.66B | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $15.44B | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $14.40B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $13.74B | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $12.30B | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $11.09B | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $10.19B | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $10.17B | Feb 18, 2020 |
| FY2016 | Dec 30, 2016 | $2.58B | Feb 24, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $17.11B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $16.58B | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $15.34B | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $14.29B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $13.62B | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $12.20B | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $10.98B | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $10.19B | Feb 23, 2021 |
| FY2018 | Dec 29, 2017 | $10.17B | Feb 19, 2019 |
| FY2018 | Dec 30, 2016 | $7.04B | Feb 19, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $1.45B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $1.25B | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $199.00M | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $685.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $753.00M | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $628.00M | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $667.00M | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $581.00M | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $366.00M | Feb 18, 2020 |
| FY2016 | Dec 30, 2016 | $59.00M | Feb 24, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $2.11B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $1.83B | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $621.00M | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $1.09B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.15B | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $998.00M | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $912.00M | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $749.00M | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $559.00M | Feb 18, 2020 |
| FY2016 | Dec 30, 2016 | $152.00M | Feb 24, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $187.00M | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $150.00M | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $128.00M | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $116.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $109.00M | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $73.00M | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $49.00M | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $46.00M | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $42.00M | Feb 18, 2020 |
| FY2018 | Dec 30, 2016 | $44.00M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $999.00M | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $983.00M | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $942.00M | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $951.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $851.00M | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $770.00M | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $689.00M | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $729.00M | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $737.00M | Feb 18, 2020 |
| FY2018 | Dec 30, 2016 | $422.00M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $1.75B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $1.44B | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $1.19B | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $992.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $1.03B | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $1.33B | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $992.00M | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $768.00M | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $526.00M | Feb 18, 2020 |
| FY2011 | Jan 31, 2012 | $772.00M | Mar 27, 2012 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jan 3, 2020 | $121.00M | Feb 18, 2020 |
| FY2019 | Dec 28, 2018 | $73.00M | Feb 18, 2020 |
| FY2019 | Dec 29, 2017 | $81.00M | Feb 18, 2020 |
| FY2018 | Dec 30, 2016 | $29.00M | Feb 19, 2019 |
| FY2017 | Jan 1, 2016 | $27.00M | Feb 23, 2018 |
| FY2016 | Jan 30, 2015 | $29.00M | Feb 24, 2017 |
| FY2016 | Jan 2, 2015 | $29.00M | Feb 24, 2017 |
| FY2015 | Jan 31, 2014 | $53.00M | Mar 25, 2015 |
| FY2015 | Jan 31, 2013 | $39.00M | Mar 25, 2015 |
| FY2013 | Jan 31, 2012 | $56.00M | Mar 27, 2014 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $13.49B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $13.01B | Feb 17, 2026 |
| FY2024 | Dec 29, 2023 | $12.70B | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $13.07B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $13.26B | Feb 14, 2023 |
| FY2021 | Jan 1, 2021 | $12.51B | Feb 15, 2022 |
| FY2020 | Jan 3, 2020 | $9.37B | Feb 23, 2021 |
| FY2019 | Dec 28, 2018 | $8.77B | Feb 18, 2020 |
| FY2018 | Dec 29, 2017 | $8.99B | Feb 19, 2019 |
| FY2017 | Dec 30, 2016 | $9.13B | Feb 23, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $8.53B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $8.55B | Feb 17, 2026 |
| FY2024 | Dec 29, 2023 | $8.44B | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $8.72B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $8.92B | Feb 14, 2023 |
| FY2021 | Jan 1, 2021 | $8.64B | Feb 15, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $4.92B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $4.41B | Feb 17, 2026 |
| FY2024 | Dec 29, 2023 | $4.20B | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $4.30B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $4.29B | Feb 14, 2023 |
| FY2021 | Jan 1, 2021 | $3.86B | Feb 15, 2022 |
| FY2020 | Jan 3, 2020 | $3.41B | Feb 23, 2021 |
| FY2019 | Dec 28, 2018 | $3.31B | Feb 18, 2020 |
| FY2018 | Dec 29, 2017 | $3.37B | Feb 19, 2019 |
| FY2017 | Dec 30, 2016 | $3.14B | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $6.34B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $6.08B | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $6.11B | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $6.70B | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $6.74B | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $6.31B | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $4.91B | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | $4.86B | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | $4.97B | Feb 18, 2020 |
| FY2018 | Dec 30, 2016 | $4.62B | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $4.65B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $3.41B | Feb 17, 2026 |
| FY2024 | Dec 29, 2023 | $2.36B | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | $2.37B | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | $1.88B | Feb 14, 2023 |
| FY2021 | Jan 1, 2021 | $1.33B | Feb 15, 2022 |
| FY2020 | Jan 3, 2020 | $896.00M | Feb 23, 2021 |
| FY2019 | Dec 29, 2018 | $420.00M | Feb 18, 2020 |
| FY2019 | Dec 28, 2018 | $372.00M | Feb 18, 2020 |
| FY2018 | Dec 30, 2017 | ($15.00M) | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | $1.11B | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | $849.00M | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | $641.00M | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | $516.00M | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | $727.00M | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | $524.00M | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | $668.00M | Feb 15, 2022 |
| FY2019 | Dec 28, 2018 | $327.00M | Feb 18, 2020 |
| FY2018 | Dec 29, 2017 | $390.00M | Feb 19, 2019 |
| FY2017 | Dec 30, 2016 | $376.00M | Feb 23, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Jan 31, 2014 | $1.33B | Mar 27, 2014 |
| FY2013 | Jan 31, 2013 | $1.30B | Mar 27, 2014 |
| FY2012 | Jan 31, 2012 | $1.85B | Mar 27, 2013 |
| FY2011 | Jan 31, 2011 | $1.85B | Mar 27, 2012 |
| FY2010 | Jan 31, 2010 | $1.11B | Mar 25, 2011 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 11 | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | 9 | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | 1 | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | 5 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | 4 | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | 4 | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | 3 | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | 2 | Feb 18, 2020 |
| FY2016 | Dec 30, 2016 | 0 | Feb 24, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 11 | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | 9 | Feb 17, 2026 |
| FY2025 | Dec 29, 2023 | 1 | Feb 17, 2026 |
| FY2024 | Dec 30, 2022 | 4 | Feb 11, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 13, 2024 |
| FY2022 | Jan 1, 2021 | 4 | Feb 14, 2023 |
| FY2021 | Jan 3, 2020 | 4 | Feb 15, 2022 |
| FY2020 | Dec 28, 2018 | 3 | Feb 23, 2021 |
| FY2019 | Dec 29, 2017 | 2 | Feb 18, 2020 |
| FY2016 | Dec 30, 2016 | 0 | Feb 24, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 126.38M | Feb 17, 2026 |
| FY2025 | Jan 3, 2025 | 131.16M | Feb 17, 2026 |
| FY2024 | Dec 29, 2023 | 135.77M | Feb 11, 2025 |
| FY2023 | Dec 30, 2022 | 136.93M | Feb 13, 2024 |
| FY2022 | Dec 31, 2021 | 140.00M | Feb 14, 2023 |
| FY2021 | Jan 1, 2021 | 142.00M | Feb 15, 2022 |
| FY2020 | Jan 3, 2020 | 141.00M | Feb 23, 2021 |
| FY2019 | Dec 28, 2018 | 146.00M | Feb 18, 2020 |
| FY2018 | Dec 29, 2017 | 151.00M | Feb 19, 2019 |
| FY2017 | Dec 30, 2016 | 150.00M | Feb 23, 2018 |